The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 1992

K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
Repligen Corporation, Cambridge, MA 02139.

To identify the principal neutralization determinant (PND) of simian immunodeficiency virus (SIV), antisera were generated using recombinant gp110 [the SIV analog of the human immunodeficiency virus type 1 (HIV-1) external envelope glycoprotein, gp120], gp140, several large recombinant and proteolytic envelope fragments, and synthetic peptides of the SIVmac251 isolate. When purified under conditions that retain its native structure, gp110 bound CD4 and elicited antisera that neutralized SIVmac251 with high titer. Native gp110 also completely inhibited neutralizing antibody in sera from SIVmac251-infected macaques. In contrast, denatured gp110 and gp140, large envelope fragments, and synthetic peptides (including peptides analogous to the HIV-1 PND) elicited very low or undetectable neutralizing antibody titers and did not inhibit neutralizing antibody in infected macaque sera. Enzymatically deglycosylated gp110 efficiently absorbed neutralizing antibodies from macaque sera, showing that neutralizing antibodies primarily bind the protein backbone. A 45-kDa protease digest product, mapping to the carboxyl-terminal third of gp110, also completely absorbed neutralizing antibodies from infected macaque sera. These results show that the PND(s) of this SIV isolate depends on the native conformation and that linear peptides corresponding to the V3 loop of SIV envelope, in contrast to that of HIV-1, do not elicit neutralizing antibody. This may affect the usefulness of SIVmac for evaluating HIV-1 envelope vaccine approaches that rely on eliciting neutralizing antibody.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011489 Protein Denaturation Disruption of the non-covalent bonds and/or disulfide bonds responsible for maintaining the three-dimensional shape and activity of the native protein. Denaturation, Protein,Denaturations, Protein,Protein Denaturations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian

Related Publications

K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
April 1992, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
June 1992, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
May 1992, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
October 2005, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
October 1991, AIDS research and human retroviruses,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
November 2006, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
January 1991, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
October 1998, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
March 2006, Journal of virology,
K Javaherian, and A J Langlois, and S Schmidt, and M Kaufmann, and N Cates, and J P Langedijk, and R H Meloen, and R C Desrosiers, and D P Burns, and D P Bolognesi
January 1992, Revista Argentina de microbiologia,
Copied contents to your clipboard!